Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non—Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

This was a phase II study of linsitinib plus erlotinib versus placebo plus erlotinib in chemotherapy-naive patients with epidermal growth factor receptor-mutation positive, advanced, non—small-cell lung cancer. Linsitinib plus erlotinib resulted in inferior outcomes compared with erlotinib alone. Li...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Lung Cancer
Κύριοι συγγραφείς: Leighl, Natasha B., Rizvi, Naiyer A., de Lima, Lopes Gilberto, Arpornwirat, Wichit, Rudin, Charles M., Chiappori, Alberto A., Ahn, Myung-Ju, Chow, Laura Q.M., Bazhenova, Lyudmila, Dechaphunkul, Arunee, Sunpaweravong, Patrapim, Eaton, Keith, Chen, Jihong, Medley, Sonja, Poondru, Srinivasu, Singh, Margaret, Steinberg, Joyce, Juergens, Rosalyn A., Gadgeel, Shirish M.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2016
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474312/
https://ncbi.nlm.nih.gov/pubmed/27686971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2016.07.007
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια